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Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most
extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased
in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by
virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens,
including Listeria monocytogenes. However, this increased potency has not been tested in vivo.
Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain
of Listeria monocytogenes EGDe in a murine infection model.
More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and
subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was
carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver
and spleen.
Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection
and therefore merits further investigation with a view to potential chemotherapeutic applications.
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Lantibiotics are ribosomally synthesized peptides pro-
duced by Gram-positive bacteria that frequently exhibit
potent antimicrobial activities against other bacteria.
Nisin A (nisin) is the most intensively investigated lanti-
biotic, and was first discovered in 1928 [1]. It has a long
history of safe use in the food industry and is approved
by the US Food and Drug Administration, by WHO and
by the EU (as natural food preservative E234) [2-4].
Nisin exhibits antimicrobial activity against many Gram-
positive bacteria, including food-borne pathogens such
as Listeria monocytogenes and Staphylococcus aureus.
Extensive post-translational modifications are carried
out during the biosynthesis of the active 34 amino acid
peptide. Specifically, serine and threonine residues in the
pro-peptide region are enzymatically dehydrated to
dehydroalanine and dehydrobutyrine (Dha and Dhb),
respectively. Lanthionine (Lan) and β-methyllanthionine* Correspondence: des.field@ucc.ie; c.hill@ucc.ie
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reproduction in any medium, provided the or(MeLan) ring structures are generated through the inter-
action of cysteine with Dha and Dhb, respectively [5-7]
(Figure 1). The N-terminal domain, containing one Lan
and two meLan rings (A, B, and C) is linked to the
C-terminal intertwined rings (D and E) by a flexible
hinge region. The antibacterial activity of nisin is exerted
via a dual action through the activity of the different
domains. The N-terminal domain binds to the pyro-
phosphate moiety of lipid II, inhibiting its transport to
the developing cell wall and therefore interfering with
cell wall biosynthesis [8]. This binding also facilitates
pore formation by the C-terminal domain within the
cell membrane, resulting in the loss of solutes from the
bacterial cell [9,10].
As a result of their highly potent biological activities,
lantibiotics have the potential to be employed as novel anti-
microbials to combat medically significant bacteria and
their multi-drug resistant forms [11-13]. Currently, a num-
ber of lantibiotics are under investigation for clinical use.
NVB302, a semi-synthetic derivative of actagardine, is in
stage I clinical trials with a view to treat infections caused
by the hospital-acquired bacteria Clostridium difficile [14].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structure of nisin A showing the location of the N-terminal domain, containing one lanthionine and two (β-methyl)
lanthionine rings (A, B, and C) linked to the C-terminal intertwined rings (D and E) by a flexible hinge region. Post-translational
modifications are highlighted as follows: dehydroalanine (Dha); dehydrobutyrine (Dhb); lanthionine (A-S-A) and (β-methyl) lanthionine (Abu-S-A).
Standard residues are represented in the single letter code. Arrow indicates location of the methionine to valine substitution (M21V) in nisin V.
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NAI-107), which targets several multi-drug resistant
(MDR) bacteria, is in late pre-clinical trials [15]. In models
of experimental infection involving mice and rats, the effi-
cacy of microbisporicin in vivo was found to be compar-
able or superior to reference compounds (vancomycin and
linezolid) in acute lethal infections induced with several
MDR microbes, including methicillin resistant Staphylo-
coccus aureus (MRSA), penicillin-intermediate Streptococ-
cus pneumonia and vancomycin resistant enterococci
(VRE) [16]. Another lantibiotic, mutacin 1140 (produced
by Streptococcus mutans) is also undergoing pre-clinical
trials [17]. Furthermore, a study involving the two peptide
lantibiotic, lacticin 3147, has recently demonstrated its
ability to prevent systemic spread of S. aureus in a murine
infection model [18].
Nisin also displays potent in vitro activity against multi-
drug resistant pathogens such as MRSA, vancomycin-
intermediate and -heterogeneous S. aureus (VISA and
hVISA, respectively) and VRE, [19-21] while natural var-
iants such as nisin F also show potential in this regard
[22]. Notably, several studies have also demonstrated the
in vivo efficacy of nisin A, [23-25] nisin Z, [26,27] and
Nisin F [28,29]. Indeed, nisin F was recently shown to
successfully treat respiratory disease caused by S. aureus K
in immunocompromised Wistar rats [28]. These animals
were infected intranasally with 4 × 105 S. aureus cells prior
to treatment with nisin F, also via the nasal route. Further-
more, nisin F was found to control the growth of S. aureus
for up to 15 minutes in mice when injected into the
peritoneal cavity [29]. Animals were dosed with 1 × 108
S. aureus cells intraperitoneally and subsequently treated
with nisin F, also via the intraperitoneal route. In a subse-
quent study, Nisin F-loaded brushite cement was shown
to prevent the growth of S. aureus Xen 36 [30]. The brush-
ite cement was subcutaneously implanted into mice and
infected with 1 × 103 S. aureus cells. Release of nisin F from
the bone cement prevented S. aureus infection for 7 days.
Despite the potency of nisin and its natural variants,
the gene encoded nature of these antimicrobials facili-
tates bioengineering thereof with a view to enhancingpotency [31]. Indeed, bioengineering of the hinge region
of nisin A has been particularly successful in generating
variants with enhanced potency against Gram-positive
pathogens [32,33]. One particular derivative, M21V (also
known as nisin V), exhibits an in vitro activity against
L. monocytogenes (the causative agent of listeriosis), and
indeed other pathogens, which is superior to that of
nisin A [34]. While these laboratory-based studies dem-
onstrate the enhanced potency of nisin V against all
Gram-positive bacteria tested thus far, it is not known if
this enhancement is also evident in vivo. In this study,
we address this issue by comparing the efficacy of nisin
A and nisin V against a lux-tagged strain of L. monocyto-
genes (EGDe::pPL2luxpHELP) using a murine infection
model and, ultimately, demonstrate the greater efficacy
of the bioengineered peptide in controlling infection.
Results/discussion
The ability of nisin A and nisin V to control a L. monocy-
togenes infection in a murine peritonitis model was inves-
tigated. Analysis was carried out through bioluminescent
imaging of the pathogen in living mice and through the
microbiological analysis of organs when mice were sa-
crificed. Bioluminescence is achieved through the use
of a strong constitutive promoter (Phelp [highly expre-
ssed Listeria promoter]) driving expression of the lux
genes of P. luminescens integrated into the chromosome
of L. monocytogenes EGDe [35]. The resulting strain
L. monocytogenes EGDe::pPL2luxpHELP is a strong light-
emitter, making it easier to follow in vivo using live in vivo
imaging systems (IVIS). Prior to commencement of the
study, the in vitro sensitivity of L. monocytogenes EGDe::
pPL2luxpHELP was assessed via deferred antagonism
assays using nisin A and nisin V producing strains and
classical broth-based minimum inhibitory concentration
assays (MIC) using purified peptide in each case. Results of
deferred antagonism assays with L. monocytogenes EGDe::
pPL2luxpHELP revealed that the nisin V producing strain
exhibited increased bioactivity (the combined impact on
production and activity) compared to that of L. lactis
NZ9700 (nisin A producing strain) (Figure 2a). This was in
Figure 2 Deferred antagonism assay and mass spectrometry
analysis of nisin A and nisin V. (a) Inhibition of growth of
L. monocytogenes EGDe::pPL2luxpHELP by the nisin A producing strain
L. lactis NZ9700 and the nisin V producing strain L. lactis NZ9800nisA::
M21V. (b) Mass spectrometry analysis of the nisin A (3353 amu) and
nisin V (3321 amu) peptides produced by the bacterial strains L. lactis
NZ9700 and L. lactis NZ9800nisA::M21V, respectively.
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similar production levels but increased specific activity of
nisin V compared to nisin A [32]. Mass spectrometry ana-
lysis of purified nisin A and nisin V peptides confirmed that
peptides of correct mass were produced (nisin A - 3353 Da;
nisin V- 3321 Da) (Figure 2b). The peptides differ by 32 Da,
consistent with the methionine21 to valine (M21V) change
of the hinge region of the peptide. Following purification,
the specific activity of nisin A and nisin V was tested
against L. monocytogenes EGDe::pPL2luxpHELP using mi-
nimum inhibitory concentration (MIC) assays. Nisin A was
found to be inhibitory at concentrations of 12.57 mg/L
(Table 1), which is consistent with the previously estab-
lished MIC for the non-lux tagged parent strain (L. mono-
cytogenes EGDe) [34]. Nisin V was found to be two-fold
more active against L. monocytogenes EGDe::pPL2lux-
pHELP, with an MIC of 6.22 mg/L. Indeed, the superior
activity of nisin V was also confirmed against a number offield and clinical strains of L. monocytogenes, where nisin V
exhibited at least a two-fold improvement against all nisin
A-resistant strains (Table 1).
For the in vivo study, mice were infected via the intra-
peritoneal route with 1 × 105 cfu of L. monocytogenes
EGDe::pPL2luxpHELP and at 30 minutes post infection
were treated intraperitoneally with doses of either nisin
A (58.82 mg/kg), nisin V (58.82 mg/kg) or PBS (negative
control). On day three of the trial, IVIS imaging was
used to quantify the level of infection through the detec-
tion of light emitted from the pathogen within the mice
(Figure 3). While the initial image suggested that nisin A
had reduced the amount of luminescence detected (rela-
tive light units or RLU), the difference was not statis-
tically significant compared to the PBS-treated control
group (Figure 4a). However, a statistically significant re-
duction (P = 0.044) in RLU measurements was observed
in the nisin V treated group when compared to the PBS
control group (Figure 4a). These results provide the first
evidence of the enhanced in vivo efficacy of nisin V rela-
tive to nisin A. In addition, microbiological analysis of the
liver and spleen was determined after the mice were
euthanized. While no statistical difference in listerial num-
bers was observed in the liver between the nisin A and
PBS-containing control groups, average pathogen num-
bers were significantly lower (P = 0.018) by over 1 log in
the livers of the nisin V-treated groups (4.70 ± 0.5 log cfu)
compared to the control group (6.27 ± 0.25 log cfu)
(Figure 4b). Analysis of spleens further highlighted the
ability of nisin V with respect to controlling L. monocyto-
genes EGDe::pPL2luxpHELP infection. In contrast to the
liver-related results, spleen cfu counts revealed that nisin
A administration had significantly reduced Listeria num-
bers (5.7 ± 0.17 log cfu) (P < 0.015) compared to the con-
trol group (6.2 ± 0.2 log cfu) (Figure 4c). However, the
number of Listeria cells in the spleens of nisin V treated
animals was significantly lower again, at 5.1 ± 0.25 log cfu,
(P < 0.015) than that of the other groups (Figure 4c).
While the application of lantibiotics in this way to control
Listeria in vivo is novel, there have been previous suc-
cesses with linear non-lantibiotic bacteriocins. Indeed, the
class IIA bacteriocins, piscicolin 126 and pediocin PA-1
have been shown to effectively control L. monocytogenes
in vivo [36,37].
Although, nisin A displays relatively low cytotoxicity
towards intestinal epithelial cells in vitro [38] and shows
no developmental toxicity in rat models [39], the cyto-
toxicity of nisin V would have to be investigated further
before consideration for use in the clinical setting. How-
ever, the fact that nisin V lacks haemolytic activity, even
at concentrations of 500 mg/L, and differs from nisin A
by just one amino acid may mean that a certain
amount of read-across will be permitted and a reduced
panel of cytoxicity tests could be sufficient to advance
Table 1 In vitro activity of nisin A and nisin V against L. monocytogenes strains as determined by minimum inhibitory
concentration assaysa
Strain Equivalent name Source/Reference Nisin A mg/L (μM) Nisin V mg/L (μM)
EGDe::pPL2luxpHELP [35] 12.57 (3.75) 6.22 (1.875)
33028b OB001102 Food 50.28 (15) 24.90 (7.5)
33077b 98-18140 Bovine tissue 50.28 (15) 24.90 (7.5)
33225b LMB0455 Unknown 25.14 (7.5) 12.45 (3.75)
F4565c 33410, FSLN3-008 Clinical (Los Angeles, California outbreak, 1985) 12.57 (3.75) 6.22 (1.875)
CD1038d Pork sausage 50.28 (15) 12.45 (3.75)
aThe standard deviation is 0 because of identical triplicate results.
bStrain acquired from Todd Ward (Agricultural Research Service, U.S. Department of Agriculture).
cStrain acquired from Martin Wiedmann (International Life Sciences Institute).
dStrain acquired from Catherine Donnelly (Department of Nutrition and Food Sciences, University of Vermont).
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which bioengineering-based strategies have been em-
ployed to enhance its solubility [40], stability [41], diffu-
sion [42] and antimicrobial activity and spectra [32,43,44]
would suggest that other derivatives can be generated toFigure 3 Analysis of effect of nisin A and nisin V on Listeria infection in m
monocytogenes EGDe::pPL2luxpHELP. Luminescence observed in animal
nisin A and (c) 58.82 mg/kg nisin V 30 minutes after Listeria infection.further improve upon the functional and pharmokinetic
properties of nisin. Alternatively, the use of nisin V in
combination with other antimicrobials, such as lysozyme
and lactoferrin [28], may also further enhance in vivo
efficacy.ice 3 days after intraperitoneal infection with 1 × 105 CFU Listeria
s injected with (a) phosphate buffered saline (PBS) (b) 58.82 mg/kg
Figure 4 (a) Relative light unit (RLU) counts in mice 3 days after
intraperitoneal infection with 1 × 105 CFU L. monocytogenes
EGDe::pPL2luxpHELP. (b) CFU data from livers and (c) spleens of
infected mice. Lines connecting groups indicate statistically
significant differences between those groups (P < 0.05).
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This study is the first in which the in vivo efficacy of a
bioengineered nisin derivative has been assessed. The
results revealed that nisin V was more effective than nisin
A with respect to controlling infection with L. monocyto-
genes in mice. Significantly, the results validate the use of
bioengineering-based strategies for peptide improvement
and design and also highlight the potential of nisin V
as a chemotherapeutic agent. Enhanced nisins could beespecially relevant in situations where traditional antibiotic
therapy has failed or where safety issues may predominate.
Importantly, the safety of nisin has been well established
with, for example, a 90-day oral toxicity study involving
rats fed a diet containing nisin A reporting a no-observed-
adverse-effect level of approximately 3000 mg/kg/day [45].
Preliminary studies with nisin V revealed a lack of haemo-
lytic activity, even at concentrations of 500 mg/L (D. Field
unpublished results).
In conclusion, this study has determined that the
enhanced potency of nisin V over nisin A is maintained
in vivo against the foodborne pathogen L. monocytogenes
EGDe and suggests that nisin V is a promising candidate
as a therapeutic agent.
Methods
Bacterial strains and growth conditions
Lactococcus lactis NZ9700 and L. lactis NZ9800nisA::
M21V strains were cultured in M17 broth (Oxoid) supple-
mented with 0.5% glucose (GM17) and GM17 agar at 30°C.
Field isolates of Listeria monocytogenes and Listeria mo-
nocytogenes EGDe::pPL2luxpHELP, which harbours the
luxABCDE operon of P. luminescens integrated into the
chromosome at a single site [35], was grown in Brain Heart
Infusion (BHI) broth (Oxoid) or BHI agar at 37°C.
Nisin purification
Purification of wild type nisin A and the derivative nisin
V were carried out as described previously [34]. Briefly,
overnight cultures of the wild type nisin A producing
strain L. lactis NZ9700 [46] and the nisin V producing
variant L. lactis NZ9800nisA::M21V [34] were grown in
GM17 broth at 30°C and were subsequently inoculated
into two litres of purified TY broth at 1% and incubated
overnight at 30°C. The culture was centrifuged at 7,000
r.p.m. for 20 minutes and the supernatant retained. The
supernatant was applied to a 60 g Amberlite bead (Sigma)
column, which was subsequently washed with 500 ml of
30% ethanol and the inhibitory activity eluted in 500 ml of
70% isopropanol 0.1% trifluoroacetic acid (TFA). The cell
pellet was resuspended in 300 ml of 70% isopropanol 0.1%
TFA and magnetically stirred for 3 hours at room tem-
perature. The cells were removed by centrifugation at
7,000 r.p.m. for 20 minutes and the supernatant retained.
The isopropanol was evaporated off using a rotary evapor-
ator (Buchi) to a volume of 160 ml and the sample pH
adjusted to approximately 4.2. The sample was applied to
a 10 g (60 ml) Varian C-18 Bond Elut Column previously
pre-equilibrated with HPLC water and methanol. The
column was washed with 120 ml of 30% ethanol and the
inhibitory activity eluted in 60 ml of 70% isopropanol 0.1%
TFA. Six millilitres of the lantibiotic preparation was con-
centrated to 1 ml through the removal of the isopropanol
by rotary evaporation and applied to a Phenomenex C12
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with 25% isopropanol 0.1% TFA. The column was then
developed in a gradient of 30% isopropanol 0.1% TFA to
60% isopropanol 0.1% TFA from 10 to 45 minutes at a
flow rate of 2.1 ml/min. Fractions containing nisin A and
nisin V peptides were collected and subjected to Mass
Spectrometry with a Shimadzu Biotech MALDI-TOF Mass
Spectrometer (AXIMA-CFR plus model).
Bioassays for antimicrobial activity
Deferred antagonism assays were carried out as pre-
viously described [34]. Briefly, 5 μl of fresh overnight
cultures of L. lactis NZ9700 and L. lactis NZ9800nisA::
M21V were spotted and allowed to grow on GM17 agar
overnight. The colonies were subjected to 30 mins UV
radiation prior to overlaying with BHI agar (0.75% w/v
agar) seeded with the indicator strain L. monocytogenes
EGDe::pPL2luxpHELP. The plates were then incubated
at 37°C overnight and relative zone size compared.
Minimum inhibitory concentration (MIC) assays
The MIC of nisin A and nisin V against Listeria monocy-
togenes EGDe::pPL2luxpHELP and several field isolates
of Listeria monocytogenes was carried out in triplicate as
previously described [34]. Briefly, prior to the addition of
purified peptides, the 96-well microtitre plates were pre-
treated with 200 μl of phosphate buffered saline (PBS)
containing 1% (w/v) bovine serum albumin (BSA) and
incubated at 37°C for 30 min. Wells were washed with
PBS and left to dry before the addition of 100 μl BHI
broth. L. monocytogenes strains were grown overnight in
BHI broth at 37°C, subcultured into fresh BHI broth and
grown to log phase (OD600nm of 0.5). The cultures were
diluted to a concentration of 1 × 105 cfu/ml in a 0.2 ml
volume. The purified peptides were resuspended in BHI
broth to a stock concentration of 60 μM and adjusted to
a 15 μM starting concentration. Two-fold dilutions of
the peptides were made in the 96-well plates, which
were subsequently inoculated with the bacterial strains
and incubated at 37°C for 16 hours. The minimum in-
hibitory concentration (MIC) was read as the minimum
peptide concentration inhibiting visible growth of the
bacterial strains.
Inoculum preparation
L. monocytogenes EGDe was grown overnight in BHI
broth at 37°C from an isolated colony growing on a BHI
agar plate containing 7.5 mg/L chloramphenicol. The
overnight culture was diluted in order to facilitate its
administration in a dose of 1 × 105 cfu/200 μl PBS.
Mouse model
All procedures involving animals were approved by the
UCC Animal Experimentation Ethics Committee andcarried out by a licensed individual with an ethical approval
number of 2011/017. For the L. monocytogenes murine
model, 15 Balb/c female mice (7 weeks old, 15 g ± 2 g in
weight) were divided into three groups (A, B and C) with
each group containing 5 mice. At T0 on day 1, all groups
were infected with 1 × 105 viable cells of L. monocytogenes
EDGe::pPL2luxpHELP in a 200 μl dose of PBS via the
intraperitoneal (I.P.) route. At T0.5hrs, mice in group A were
administered PBS (control), group B were treated with
nisin A (58.82 mg/kg) and group C treated with nisin V
(58.82 mg/kg). Both PBS and the nisin peptides were admi-
nistered in 200 μl doses via the I.P. route. On day 3, the
mice were anaesthetised using a mixture of aerosolised
isoflurane and oxygen. Bioluminescence was monitored
using an IVISW Imaging System 100 series (Xenogen Cor-
poration, Almeda, CA) with a 5 minute exposure time.
Immediately afterward, the mice were euthanized and the
livers and spleens were extracted. The organs were mech-
anically disrupted and serial dilutions made which were
subsequently plated in 100 μl volumes on BHI agar plates
containing chloramphenicol 7.5 mg/L in order to enume-
rate L. monocytogenes present in each organ.
Luminescence quantification
IVIS imaging software was used to carry out quantification
of luminescence. Bioluminescence emitted from the infec-
tion site was measured as total counts across the region of
interest (designated relative light units – “RLU”) and was
averaged across all groups of mice. The reduction in lumi-
nescence was quantified and represents a comparison with
the luminescence from mice administered PBS control at
the same time point.
Statistical analysis
CFU and RLU data was transformed to log10 prior to ana-
lysis. All comparisons were based on the mean ± standard
error of the mean (SEM). Parametric data was analysed
using one way analysis of variance (ANOVA) with post
hoc comparison using the Student-Newman-Keuls me-
thod. Non-parametric data was analysed by the Kruskal–
Wallis one way ANOVA with post hoc comparison as
above. P < 0.05 was considered to be significant in all cases.
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